About Auxogyn

Auxogyn – Advancing women’s reproductive health through novel scientific and clinical knowledge of early human developmental biology

• auxology (from Greek αὔξω, auxō, or αὐξάνω, auxanō, "growth") is a meta-term covering the study of human growth and biology
• gynaecology or gynecology (from Greek gynaikos meaning woman) is the medical practice dealing with the health of the female reproductive system. Literally, outside medicine, it means "the science of women".

Auxogyn was incorporated in 2008 under the leadership of Professor Renee Reijo Pera in collaboration with colleagues Dr. Barry Behr, Dr. Thomas Baer, and post-doctoral fellows Dr. Connie Wong and Dr. Kevin Loewke. The pioneering science and technology was developed over several years at the Stanford Institute for Stem Cell Biology & Regenerative Medicine.

In May 2010, Auxogyn was funded by Kleiner Perkins Caufield & Byers, TPG Biotechnology and Merck Serono Ventures and the Company was launched.

Auxogyn’s first product, the Early Embryo Viability Assessment (Eeva) System, is designed to address the need for a consistent, proven method for assessing embryo viability during in vitro fertilization procedures. The Eeva System may help embryologists identify, at cleavage stage, which embryo(s) are most likely to continue development into blastocyst(s), a critical time point in development which happens at day 5. When used with conventional embryo grading methods, the Eeva System has the potential to give IVF clinics and their patients greater opportunity for success.

In addition to the Eeva System, Auxogyn is committed to developing additional innovative products to address the growing number of patients suffering from infertility today.

Our Mission

We will positively impact the lives of families by providing innovative technologies to address unmet needs in reproductive health.

We embrace the highest standards of scientific and clinical integrity to maximize value for our patients, medical professionals, employees and stakeholders.